449 related articles for article (PubMed ID: 26871945)
1. Effective growth-suppressive activity of maternal embryonic leucine-zipper kinase (MELK) inhibitor against small cell lung cancer.
Inoue H; Kato T; Olugbile S; Tamura K; Chung S; Miyamoto T; Matsuo Y; Salgia R; Nakamura Y; Park JH
Oncotarget; 2016 Mar; 7(12):13621-33. PubMed ID: 26871945
[TBL] [Abstract][Full Text] [Related]
2. TOPK (T-LAK cell-originated protein kinase) inhibitor exhibits growth suppressive effect on small cell lung cancer.
Park JH; Inoue H; Kato T; Zewde M; Miyamoto T; Matsuo Y; Salgia R; Nakamura Y
Cancer Sci; 2017 Mar; 108(3):488-496. PubMed ID: 28075524
[TBL] [Abstract][Full Text] [Related]
3. Oncogenic roles of TOPK and MELK, and effective growth suppression by small molecular inhibitors in kidney cancer cells.
Kato T; Inoue H; Imoto S; Tamada Y; Miyamoto T; Matsuo Y; Nakamura Y; Park JH
Oncotarget; 2016 Apr; 7(14):17652-64. PubMed ID: 26933922
[TBL] [Abstract][Full Text] [Related]
4. MELK inhibition targets cancer stem cells through downregulation of SOX2 expression in head and neck cancer cells.
Ren L; Deng B; Saloura V; Park JH; Nakamura Y
Oncol Rep; 2019 Apr; 41(4):2540-2548. PubMed ID: 30720113
[TBL] [Abstract][Full Text] [Related]
5. Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma.
Chlenski A; Park C; Dobratic M; Salwen HR; Budke B; Park JH; Miller R; Applebaum MA; Wilkinson E; Nakamura Y; Connell PP; Cohn SL
Mol Cancer Ther; 2019 Mar; 18(3):507-516. PubMed ID: 30674566
[TBL] [Abstract][Full Text] [Related]
6. Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia.
Alachkar H; Mutonga MB; Metzeler KH; Fulton N; Malnassy G; Herold T; Spiekermann K; Bohlander SK; Hiddemann W; Matsuo Y; Stock W; Nakamura Y
Oncotarget; 2014 Dec; 5(23):12371-82. PubMed ID: 25365263
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
[TBL] [Abstract][Full Text] [Related]
8. High expression of maternal embryonic leucine-zipper kinase (MELK) impacts clinical outcomes in patients with ovarian cancer and its inhibition suppresses ovarian cancer cells growth ex vivo.
Ikeda Y; Sato S; Yabuno A; Shintani D; Ogasawara A; Miwa M; Zewde M; Miyamoto T; Fujiwara K; Nakamura Y; Hasegawa K
J Gynecol Oncol; 2020 Nov; 31(6):e93. PubMed ID: 33078598
[TBL] [Abstract][Full Text] [Related]
9. MELK-T1, a small-molecule inhibitor of protein kinase MELK, decreases DNA-damage tolerance in proliferating cancer cells.
Beke L; Kig C; Linders JT; Boens S; Boeckx A; van Heerde E; Parade M; De Bondt A; Van den Wyngaert I; Bashir T; Ogata S; Meerpoel L; Van Eynde A; Johnson CN; Beullens M; Brehmer D; Bollen M
Biosci Rep; 2015 Oct; 35(6):. PubMed ID: 26431963
[TBL] [Abstract][Full Text] [Related]
10. Maternal embryonic leucine zipper kinase: A novel biomarker and a potential therapeutic target of cervical cancer.
Wang J; Wang Y; Shen F; Xu Y; Zhang Y; Zou X; Zhou J; Chen Y
Cancer Med; 2018 Nov; 7(11):5665-5678. PubMed ID: 30334367
[TBL] [Abstract][Full Text] [Related]
11. MELK is an oncogenic kinase essential for early hepatocellular carcinoma recurrence.
Xia H; Kong SN; Chen J; Shi M; Sekar K; Seshachalam VP; Rajasekaran M; Goh BKP; Ooi LL; Hui KM
Cancer Lett; 2016 Dec; 383(1):85-93. PubMed ID: 27693640
[TBL] [Abstract][Full Text] [Related]
12. Involvement of maternal embryonic leucine zipper kinase (MELK) in mammary carcinogenesis through interaction with Bcl-G, a pro-apoptotic member of the Bcl-2 family.
Lin ML; Park JH; Nishidate T; Nakamura Y; Katagiri T
Breast Cancer Res; 2007; 9(1):R17. PubMed ID: 17280616
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor.
Chung S; Kijima K; Kudo A; Fujisawa Y; Harada Y; Taira A; Takamatsu N; Miyamoto T; Matsuo Y; Nakamura Y
Oncotarget; 2016 Apr; 7(14):18171-82. PubMed ID: 26918358
[TBL] [Abstract][Full Text] [Related]
14. Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells.
Nakano I; Masterman-Smith M; Saigusa K; Paucar AA; Horvath S; Shoemaker L; Watanabe M; Negro A; Bajpai R; Howes A; Lelievre V; Waschek JA; Lazareff JA; Freije WA; Liau LM; Gilbertson RJ; Cloughesy TF; Geschwind DH; Nelson SF; Mischel PS; Terskikh AV; Kornblum HI
J Neurosci Res; 2008 Jan; 86(1):48-60. PubMed ID: 17722061
[TBL] [Abstract][Full Text] [Related]
15. Maternal embryonic leucine zipper kinase serves as a poor prognosis marker and therapeutic target in osteosarcoma.
Jeddo SFA; Wei X; Li K; Li X; Yang Q; Dongol S; Li J
Oncol Rep; 2020 Sep; 44(3):1037-1048. PubMed ID: 32705239
[TBL] [Abstract][Full Text] [Related]
16. Casticin suppresses the carcinogenesis of small cell lung cancer H446 cells through activation of AMPK/FoxO3a signaling.
Gong Q; Cao X; Cao J; Yang X; Zeng W
Oncol Rep; 2018 Sep; 40(3):1401-1410. PubMed ID: 30015975
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of human serine/threonine kinase 33 suppresses human small cell lung carcinoma by blocking RPS6/BAD signaling transduction.
Sun EL; Liu CX; Ma ZX; Mou XY; Mu XA; Ni YH; Li XL; Zhang D; Ju YR
Neoplasma; 2017; 64(6):869-879. PubMed ID: 28895411
[TBL] [Abstract][Full Text] [Related]
18. MELK and EZH2 Cooperate to Regulate Medulloblastoma Cancer Stem-like Cell Proliferation and Differentiation.
Liu H; Sun Q; Sun Y; Zhang J; Yuan H; Pang S; Qi X; Wang H; Zhang M; Zhang H; Yu C; Gu C
Mol Cancer Res; 2017 Sep; 15(9):1275-1286. PubMed ID: 28536141
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of maternal embryonic leucine zipper kinase with OTSSP167 displays potent anti-leukemic effects in chronic lymphocytic leukemia.
Zhang Y; Zhou X; Li Y; Xu Y; Lu K; Li P; Wang X
Oncogene; 2018 Oct; 37(41):5520-5533. PubMed ID: 29895969
[TBL] [Abstract][Full Text] [Related]
20. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
